Resource impact statement
No significant resource impact is anticipated
NICE has recommended brolucizumab as an option for treating visual impairment due to diabetic macular oedema in adults, only if:
- the eye has a central retinal thickness of 400 micrometres or more at the start of treatment
- the company provides brolucizumab according to the commercial arrangement.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).
This is because the technology is a further treatment option and the overall cost of treatment will be similar.
Brolucizumab has a discount that is commercial in confidence. For enquiries about the patient access scheme contact commercial.team@novartis.com for details.
This technology is commissioned by integrated care systems. Providers are NHS Hospital Trusts.
This page was last updated: